Lianhe Global has upgraded the global scale Long-term Issuer Credit Rating of Taizhou Huaxin Pharmaceutical Investment Co., Ltd. to ‘A’ from ‘A-’; Issuer Rating Remains Outlook Stable

HONG KONG, 14 September 2026 – Lianhe Ratings Global Limited (“Lianhe Global”), an international credit rating company, has upgraded the global scale Long-term Issuer Credit Rating of Taizhou Huaxin Pharmaceutical Investment Co., Ltd. (“THPI”) to ‘A’ from ‘A-’; Issuer Rating Outlook Remains Stable.